A Study to Evaluate the Efficacy and Safety of AD-208

Phase 3CompletedNCT04825561

Addpharma Inc.139 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of AD-208.

The purpose of this study is to evaluate the efficacy and safety of AD-208 in male patients with androgenetic alopecia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

139

Conditions

Androgenetic Alopecia

Interventions

AD-208DRUG

PO, Once daily(QD), 24weeks

AD-2081DRUG

PO, Once daily(QD), 24weeks

placebo of AD-208DRUG

PO, Once daily(QD), 24weeks

placebo of AD-2081

Eligibility

Sex: MALEMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male patients aged 18-50 years, inclusive * Patients who meet the appropriate criteria according to the classification of hair loss * Signed informed consent Exclusion Criteria: * Patients with hair loss disorders other than androgenetic alopecia * Other exclusions applied

Locations (1)

The Catholic University of Korea, Eunpyeong St. Mary's Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

The amount of Change in the total number of hairs

The amount of change in the total number of hairs in the unit area

Time frame: Baseline, Week 24

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.